欧林生物: 成都欧林生物科技股份有限公司信息披露暂缓与豁免事务管理制度（2025年7月）

Core Viewpoint - The document outlines the management system for the temporary suspension and exemption of information disclosure by Chengdu Olin Biotechnology Co., Ltd, emphasizing compliance with relevant laws and regulations while ensuring the protection of state and commercial secrets [1][2]. Group 1: General Principles - The company aims to standardize the temporary suspension and exemption of information disclosure to ensure compliance with the Company Law, Securities Law, and other relevant regulations [1]. - Information disclosure obligations must be fulfilled accurately, completely, and timely, without misuse of suspension or exemption to mislead investors or engage in illegal activities [1][2]. Group 2: Scope of Suspension and Exemption - The company can exempt disclosure if the information involves state secrets or could violate confidentiality regulations, ensuring that no state secrets are leaked through any form of communication [2][3]. - Commercial secrets can be temporarily suspended or exempted from disclosure if they meet specific criteria, such as potential harm from disclosure or infringement of others' commercial secrets [2][3]. Group 3: Internal Management of Suspension and Exemption - The company must follow internal review procedures before implementing any suspension or exemption, maintaining records of the reasons and processes involved [4][5]. - A mechanism for accountability is established for any non-compliance with the disclosure regulations, with potential disciplinary actions for responsible personnel [5]. Group 4: Reporting and Documentation - The company is required to submit documentation of any suspended or exempted disclosures to the relevant regulatory bodies within ten days after the publication of periodic reports [4][5]. - Detailed records must be kept regarding the nature of the exempted information, the internal review process, and any potential impacts on the company or third parties [4][5].